APA

Muggia F. M., Liu P. Y., Alberts D. S., Wallace D. L., O'Toole R. V., Terada K. Y., Franklin E. W., Herrer G. W., Goldberg D. A. & Hannigan E. V. (19960712). Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group. : Gynecologic oncology.

Chicago

Muggia F M, Liu P Y, Alberts D S, Wallace D L, O'Toole R V, Terada K Y, Franklin E W, Herrer G W, Goldberg D A and Hannigan E V. 19960712. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group. : Gynecologic oncology.

Harvard

Muggia F. M., Liu P. Y., Alberts D. S., Wallace D. L., O'Toole R. V., Terada K. Y., Franklin E. W., Herrer G. W., Goldberg D. A. and Hannigan E. V. (19960712). Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group. : Gynecologic oncology.

MLA

Muggia F M, Liu P Y, Alberts D S, Wallace D L, O'Toole R V, Terada K Y, Franklin E W, Herrer G W, Goldberg D A and Hannigan E V. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group. : Gynecologic oncology. 19960712.